Naltrexone/Bupropion

Phase 3Small molecule

Novo Nordisk

Naltrexone/Bupropion is one of 30 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

GastrectomyRecruiting

Breast CancerPreclinical

Active, not recruiting

GastrectomyPhase 3

Recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Naltrexone/Bupropion

Novo Nordisk

Phase 3

1 2

Lexiscan

Astellas

Preclinical

1 3

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 4

Tianeptine

Pfizer

Preclinical

1 5

Ablavar

LLantheus Medical Imaging

Preclinical

2 6

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 7

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

2 8

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

1 9

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 10

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Post-ApprovalRecruiting

Gastrectomy

NCT06620562

Clinical

Trials by Indication[1]

Obesity4 trials

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT05579249·500 enrolled

Anti-obesity Pharmacotherapy and Inflammation

Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled

Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery

Withdrawn·OOslo University Hospital·Phase 4·NCT04399395

Show 1 more trial

Individualized Obesity Pharmacotherapy

Completed·MMayo Clinic·Phase 3·NCT03374956·193 enrolled

Metformin1 trial

Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants

Completed·OOrexigen Therapeutics, Inc·Phase 1·NCT02745912·30 enrolled

Breast Cancer1 trial

Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients

Completed·GGangnam Severance Hospital·N/A·NCT03581630·72 enrolled

Gastrectomy1 trial

Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet

Recruiting·LLaval University·Phase 4·NCT06620562·108 enrolled

Type 2 Diabetes1 trial

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

Terminated·TThe Cleveland Clinic·Phase 4·NCT04531176·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Naltrexone/Bupropion. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Naltrexone/Bupropion compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Naltrexone/Bupropion. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novo Nordisk

Naltrexone/Bupropion

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Obesity4 trials

Metformin1 trial

Breast Cancer1 trial

Gastrectomy1 trial

Type 2 Diabetes1 trial

References

Drug Info

Quick Facts

Related News